Premium skin care brand Clinical Skin has announced its acquisition of Pierre Fabre Laboratories brand Glytone. The 30-plus-year-old brand is known for being “a market pioneer in the use of active acids; each formula features active acids to target and treat difficult-to-manage skin conditions,” as detailed in a recent press release. Clinical Skin’s acquisition “reiterates a continued commitment to enhancing its unrivaled product portfolio and expanding its presence in the skin care industry,” the release confirmed.
To learn more about the strategy behind the acquisition, including Clinical Skin’s long-term growth strategy, Glytone’s place in the company’s current portfolio, and the plans for further expansion in the cosmeceutical skin care industry, we spoke to Jamie Castle, CEO of Clinical Skin for her insights.
Castle’s over 20 years of experience in the beauty industry include working with companies like Medicis, Solta, and Obagi. At Clinical Skin, her focus lies in “blending innovation with luxury to redefine beauty standards globally,” she said.
Acquisition background
Castle explained, “Clinical Skin’s decision to acquire Glytone from Pierre Fabre Laboratories stems from our unwavering commitment to offering transformative skin care solutions firmly rooted in science and innovation.” Furthermore, she added, “this strategic acquisition reiterates a continued commitment to enhancing our unrivaled product portfolio and expanding our presence in the skin care industry.”
She said the addition of Glytone to the company’s product portfolio “aligns perfectly with our mission to continue to scale our offering of skin care solutions that are firmly backed by science and innovation.” As a brand rooted in ingredient-driven product formulation processes, Glytone’s “unique attributes, particularly its use of Free Glycolic Acid and its targeted skin care solutions, complement our existing offerings and strengthen our position in the skin care market,” Castle shared.
A “respected and trusted brand in the niche physician-dispensed channel for decades,” Castle explained, Glytone was “first to understand and market the concept of Precision Free Acid, a breakthrough notion that would launch their professional peel portfolio and targeted treatments, ultimately having tremendous impact on a wide patient community and commonly addressing dermatologic needs.”
Therefore, she elucidated, “Glytone is a problem-solving skin care brand that provides efficacious customizable regimens through its in-office peel systems and at-home products.” This extensive peel and body portfolio makes it a market pioneer and a perfect fit for Clinical Skin’s goals to expand its brand presence.
Plans for the future
Moving forward, Castle confirmed, “we are committed to continuing Glytone’s rich legacy, investing in product development, technology mastering and knowledge, and brand awareness.” This includes a long-term growth strategy with a focus on “bolstering existing formulas, launching new products, and taking the brand to new heights,” she said, incorporating “Glytone’s commitment to quality and efficacy, [which] complements our own values.”
As a premium skin care company, Clinical Skin “remains committed to further expansion in the cosmeceutical skin care category…[and] we are constantly exploring innovative avenues to revolutionize the skin care landscape,” shared Castle. Therefore, “through strategic partnerships, product development initiatives, and consumer-centric approaches, we aim to reinforce our position as industry leaders while continuing to meet the evolving demands of our discerning clientele,” she explained.
As “the acquisition of Glytone marks a pivotal moment in Clinical Skin’s journey towards redefining beauty standards,” Castle concluded, “together, with Dr. Laurence Dryer and our dedicated team, we will continue to push boundaries, unlock new possibilities, and transform the skin care experience—one radiant skin at a time.”
